Hung K‐C, Sun C‐K, Chen J‐Y, Wang H‐C, Kao C‐H. Association between abdominal hernia and the risk of subsequent dementia. Brain Behav. 2019;9:e01434 10.1002/brb3.1434 31588690

1. INTRODUCTION {#brb31434-sec-0005}
===============

Dementia, which is one of the most common neurodegenerative diseases, is characterized by its slow progressive impairment of memory together with at least one more cognitive domain (Caselli, [2003](#brb31434-bib-0007){ref-type="ref"}). Nonvascular dementia (e.g., Alzheimer\'s disease \[AD\]), which accounts for 80%--90% of cases, is the most common type followed by vascular dementia and Lewy body dementia (Morris, [2003](#brb31434-bib-0023){ref-type="ref"}). The prevalence of dementia tends to increase with aging, while a growing body of evidence supported a variety of disorders (e.g., diabetes, hypertension, ischemic heart disease, chronic obstructive pulmonary disease, heart failure, depression, dyslipidemia, head injury, and stroke) as risk factors (Kohler, Buntinx, Palmer, & Akker, [2015](#brb31434-bib-0017){ref-type="ref"}; Poblador‐Plou et al., [2014](#brb31434-bib-0026){ref-type="ref"}; Qiu, Xu, & Fratiglioni, [2010](#brb31434-bib-0028){ref-type="ref"}; Sahathevan, Brodtmann, & Donnan, [2012](#brb31434-bib-0032){ref-type="ref"}). It was estimated that the number of demented patients will double every 20 years, reaching 65.7 million by the year 2030 (Prince et al., [2013](#brb31434-bib-0027){ref-type="ref"}), thereby imposing substantial social and financial burdens on global health services.

Multiple neuropathologic processes involved in neurodegenerative and vascular diseases may contribute to the development of dementia. Previous studies have proposed an important role of matrix metalloproteinases (MMPs) in precipitating pathological changes in the brain and the blood--brain barrier (e.g., blood--brain barrier leakage, neuroinflammation, and neurodegeneration; Kim & Joh, [2012](#brb31434-bib-0016){ref-type="ref"}; Mroczko, Groblewska, & Barcikowska, [2013](#brb31434-bib-0024){ref-type="ref"}; Rempe, Hartz, & Bauer, [2016](#brb31434-bib-0029){ref-type="ref"}; Rosenberg, [2009](#brb31434-bib-0030){ref-type="ref"}; Weekman & Wilcock, [2016](#brb31434-bib-0035){ref-type="ref"}). For example, elevated levels of MMP‐9 as well as changes in the MMP/tissue inhibitors of MMPs (TIMP) balance in the plasma of AD patients were found (Lorenzl et al., [2003](#brb31434-bib-0021){ref-type="ref"}; Lorenzl, Buerger, Hampel, & Beal, [2008](#brb31434-bib-0022){ref-type="ref"}). Another study demonstrated that imbalances between TIMPs and MMPs are involved in blood--brain barrier breakdown and are implicated in the human immunodeficiency virus (HIV) type 1‐associated neurocognitive disorders (Xing et al., [2017](#brb31434-bib-0036){ref-type="ref"}).

The pathogenesis underlying abdominal wall hernia is multifactorial, and current evidence suggests that the formation of abdominal hernia may be associated with disturbances in extracellular matrix turnover and connective tissue metabolism (Antoniou et al., [2011](#brb31434-bib-0002){ref-type="ref"}; Antoniou, Antoniou, Granderath, & Simopoulos, [2009](#brb31434-bib-0003){ref-type="ref"}; Franz, [2008](#brb31434-bib-0010){ref-type="ref"}; Henriksen, Yadete, Sorensen, Ågren, & Jorgensen, [2011](#brb31434-bib-0013){ref-type="ref"}). For instance, MMPs (e.g., MMP‐1, MMP‐2, MMP‐9, MMP‐13) appear to be involved in inguinal hernia or recurrent inguinal hernia development (Antoniou et al., [2011](#brb31434-bib-0002){ref-type="ref"}, [2009](#brb31434-bib-0003){ref-type="ref"}). Considering that the pathogenesis for both hernia and dementia may be associated with MMPs, there may be a missing link between hernias and dementia. We hypothesize that adult patients with hernias may be at an increased risk for dementia. To test this hypothesis, we conducted a nationwide, population‐based cohort study to examine the relationship between middle‐aged (i.e., 45 years or older) patients with hernias and dementia.

2. METHODS {#brb31434-sec-0006}
==========

2.1. Data source {#brb31434-sec-0007}
----------------

The National Health Insurance (NHI) program, which had a coverage rate of approximately 99% under mandatory enrollment, was initiated in 1995 for the purpose of providing comprehensive healthcare for residents and citizens in Taiwan. The present study adopted Longitudinal Health Insurance Database (LHID) for analysis, which is a subdatabase of the NHI program with one million individuals and their information of demographic characteristics, inpatient admissions, outpatient visits, and drug prescriptions. For all subjects in the database, the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) was applied to identify their disease histories. The Research Ethics Committee of China Medical University and Hospital (CMUH104‐REC2‐115‐CR3) reviewed and approved the protocol of the present study.

2.2. Identification of study patients and control group {#brb31434-sec-0008}
-------------------------------------------------------

Patients aged 45 years and older with the diagnosis of abdominal hernias (ICD‐9‐CM codes 550.xx‐553.xx) between January 1, 2000, and December 31, 2008, were included as the hernia group (Figure [1](#brb31434-fig-0001){ref-type="fig"}). The database was searched for the study population to identify any hospitalized event with hernia as one of the discharge diagnoses and used outpatient claims to identify any visit for hernia. Patients were classified as having hernia if they had two or more outpatient visits with a hernia diagnostic code or at least one hospital admission with a diagnostic code of hernia within 365 calendar days. The first date of outpatient visit or hospital admission date that met the selection criteria for hernias, whichever came first, was considered the index date. Patients who had a history of dementia (ICD‐9‐CM codes 290, 294.1, and 331.0, respectively) diagnosed before or on the index date, died before index date as well as those with missing information (e.g., age or sex) were excluded. Besides, patients with a history of acquired immunodeficiency syndrome were also excluded. For each patient with a hernia, one insured patient without a history of hernia or diseases (i.e., dementia or acquired immunodeficiency syndrome) before and on the index date were randomly assigned to the nonhernia group. Frequency matching with age, sex, urbanization level, socioeconomic status, and all comorbidities at ratio of 1:1 was adopted for the case and comparison cohort.

![Flow chart for selection of study patients and follow‐up process. AIDS, acquired immunodeficiency syndrome](BRB3-9-e01434-g001){#brb31434-fig-0001}

The baseline comorbidities of hypertension (ICD‐9‐CM 401‐405), diabetes mellitus (DM, ICD‐9‐CM 250), chronic obstructive pulmonary disease (COPD, ICD‐9‐CM 491, 492, and 496), depression (ICD‐9‐CM 296.2, 296.3, 296.82, 300.4, and 311), coronary artery disease (CAD, ICD‐9‐CM 410‐414), head injury (ICD‐9‐CM 310.2, 800, 801, 803, 804, 850, 851, 853, and 854), stroke (ICD‐9‐CM 430‐438), chronic kidney disease (CKD, ICD‐9‐CM 580, 581--589, 753, 403, 404, 250.4, 274.1, 440.1, 442.1, 447.3, 572.4, 642.1, and 646.2), congestive heart failure (CHF, ICD‐9‐CM 428), obesity (ICD‐9‐CM 278.00, 278.01 278, 649.1, and 783.1), hyperlipidemia (ICD‐9‐CM 272), alcoholism‐related disease (ICD‐9‐CM 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, and V11.3), and smoking (ICD‐9‐CM 305.1, 649.0, and 490--496) were identified. In addition, Charlson Comorbidity Index (CCI; Charlson, Pompei, Ales, & MacKenzie, [1987](#brb31434-bib-0009){ref-type="ref"}), which contains 17 weighted comorbidities, was also calculated for each participant. Definition of comorbidities was the presence of diagnosis codes in at least two outpatient claims or one inpatient claim. For the socioeconomic status, we classified those with a well‐defined monthly wage into three categories: New Taiwan dollar (NTD) \<20,000, 20,000--39,999, ≥40,000. The urbanization level was categorized into four levels according to population density of the residential area defined by the Taiwanese National Institutes of Health with level 1 being the most urbanized and level 4 being the least urbanized (Liu et al., [2006](#brb31434-bib-0020){ref-type="ref"}).

2.3. Study outcomes and follow‐up {#brb31434-sec-0009}
---------------------------------

Our primary outcomes were pooled incidence rates of dementia defined as at least two outpatient visits or one hospital admission with related diagnosis codes, in patients with or without hernias. All participants were followed till the occurrence of dementia, termination of study follow‐up (i.e., December 31, 2013), or death (i.e., withdrawal from the insurance system), whichever came first.

2.4. Statistics {#brb31434-sec-0010}
---------------

Because this was a retrospective study, we did not a priori power calculations. Baseline characteristics were presented as mean (standard deviation) or numbers (percent), and group difference was measured by *t* test or Pearson *χ* ^2^ test for continuous and categorical variables, respectively. The incidence rate of dementia was defined as the total number of dementia diagnosis divided by the total sum of follow‐up years (i.e., per 1,000 person‐years), and the cumulative incidence curves were compared by Kaplan--Meier method with the difference being tested by log‐rank test between hernia and comparison cohort. Cox proportional hazard model was applied in the study to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of primary outcomes. For multivariate models, the study adjusted age, sex, and any significant variables in crude model for the outcome. All statistical analyses were performed with SAS 9.4 software (SAS Institute Inc.) and R software (R Foundation for Statistical Computing). Statistical significance was defined as a two‐tailed *p*‐value \<.05.

3. RESULTS {#brb31434-sec-0011}
==========

The study included 4,784 newly diagnosed hernia participants, and 4,784 nonhernia participants after matching, and the demographic characteristics were shown in Table [1](#brb31434-tbl-0001){ref-type="table"}. There were no differences in distribution of age group, sex, socioeconomic status, urbanization level, and all comorbidities between two cohorts. There was higher prevalence in age group (46--64 years, 54.93% vs. 54.72%), male (both 82.44%), socioeconomic status (NTD \< 20,000, both 57.4%), urbanization level (level 2, both 30.2%) in hernia, and comparison cohort. The mean follow‐up intervals in the hernia participants and nonhernia participants were 8.81 ± 3.22 and 9.01 ± 3.06 years (*p* = .0024), respectively. With a reference group of nonhernia participants, significant higher risk of dementia was observed in hernia participants (HR, 1.23; 95% CI, 1.06--1.43; *p* = .0077) in crude Cox proportional hazard model; moreover, the hernia participants showed consistent result with crude model in the multivariate model after adjusting age group, sex, and significant variables in crude model, namely socioeconomic status, hypertension, diabetes, coronary artery disease, stroke, COPD, CKD, CHF, hyperlipidemia, smoking, and CCI (Table [2](#brb31434-tbl-0002){ref-type="table"}). In addition, advanced age, hypertension, head injury, and stroke were found to be significant risk factors for dementia, while a high socioeconomic status and history of coronary artery disease appeared to be protective against the development of the disorder in our cohort study (Table [2](#brb31434-tbl-0002){ref-type="table"}). Table [3](#brb31434-tbl-0003){ref-type="table"} presented the subgroup analysis of dementia risk between hernia and nonhernia cohort. Compared with nonhernia cohort, participants who diagnosed with hernia had significant higher risk to develop dementia in male gender, socioeconomic status of \<20,000, urbanization level 1, with and without congestive heart failure, without hypertension, with comorbidities of diabetes, depression, CAD, head injury, stroke, COPD, CKD, hyperlipidemia, obesity, smoking, and alcoholism‐related disease. Figure showed the Kaplan--Meier curve for the cumulative risk of dementia for hernia and nonhernia cohort, where a significant difference was observed between the two cohorts (*p* = .0075 by log‐rank test, Figure [2](#brb31434-fig-0002){ref-type="fig"}).

###### 

Comparison of demographics and comorbidity between hernia patients and controls

                                                              Hernia          *p*‐Value[b](#brb31434-note-0004){ref-type="fn"}                                                          
  ----------------------------------------------------------- --------------- -------------------------------------------------- ---------------------------------------------- ------- --------
  Age, years                                                                                                                                                                            
  45--64                                                      2,628           54.93                                              2,618                                          54.72   .8649
  65--74                                                      1,307           27.32                                              1,297                                          27.11   
  ≥75                                                         849             17.75                                              869                                            18.16   
  Mean (*SD*)                                                 63.18 (11.13)   63.46 (11.05)                                      .2201[a](#brb31434-note-0003){ref-type="fn"}           
  Gender                                                                                                                                                                                
  Female                                                      840             17.56                                              840                                            17.56   1.0000
  Male                                                        3,944           82.44                                              3,944                                          82.44   
  Socioeconomic status (NTD)                                                                                                                                                            
  \<20,000                                                    2,746           57.40                                              2,746                                          57.40   1.0000
  20,000--39,999                                              1,404           29.35                                              1,404                                          29.35   
  ≥40,000                                                     634             13.25                                              634                                            13.25   
  Urbanization level[c](#brb31434-note-0005){ref-type="fn"}                                                                                                                             
  Level 1                                                     1,390           29.06                                              1,390                                          29.06   1.0000
  Level 2                                                     1,445           30.20                                              1,445                                          30.20   
  Level 3                                                     729             15.24                                              729                                            15.24   
  Level 4                                                     1,220           25.50                                              1,220                                          25.50   
  Comorbidity                                                                                                                                                                           
  Hypertension                                                1,903           39.78                                              1,903                                          39.78   1.0000
  Diabetes                                                    586             12.25                                              586                                            12.25   1.0000
  Coronary artery disease                                     1,061           22.18                                              1,061                                          22.18   1.0000
  Head injury                                                 85              1.78                                               85                                             1.78    1.0000
  Depression                                                  51              1.07                                               51                                             1.07    1.0000
  Stroke                                                      410             8.57                                               410                                            8.57    1.0000
  Chronic obstructive pulmonary disease                       1,001           20.92                                              1,001                                          20.92   1.0000
  Chronic kidney disease                                      303             6.33                                               303                                            6.33    1.0000
  Congestive heart failure                                    126             2.63                                               126                                            2.63    1.0000
  Hyperlipidemia                                              722             15.09                                              722                                            15.09   1.0000
  Obesity                                                     2               0.04                                               2                                              0.04    1.0000
  Smoking                                                     1,300           27.17                                              1,300                                          27.17   1.0000
  Alcoholism‐related disease                                  22              0.46                                               22                                             0.46    1.0000
  Charlson Comorbidity Index                                                                                                                                                            
  0                                                           1,332           27.84                                              1,332                                          27.84   1.0000
  1                                                           834             17.43                                              834                                            17.43   
  ≥2                                                          2,618           54.72                                              2,618                                          54.72   

Data presented as mean ± *SD*, or *n* (%).

Abbreviations: NTD, new Taiwan dollar; *SD*, standard deviation.

*t* test.

Chi‐square test.

Urbanization levels categorized into 4 levels by population density of the residential area with level 1 being the most urbanized and level 4 being the least urbanized.
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###### 

Cox model with hazard ratios and 95% confidence intervals of dementia‐associated hernia and other factors in study population

  Variable                     Dementia no. (*n* = 682)   Crude[a](#brb31434-note-0007){ref-type="fn"}   Adjusted[b](#brb31434-note-0008){ref-type="fn"}                                  
  ---------------------------- -------------------------- ---------------------------------------------- ------------------------------------------------- --------- ------ ------------- ---------
  Hernia                                                                                                                                                                                  
  No                           310                        1.00                                           Reference                                                   1.00   Reference      
  Yes                          372                        1.23                                           1.06, 1.43                                        .0077     1.24   1.07, 1.45    .0047
  Gender                                                                                                                                                                                  
  Female                       125                        1.00                                           Reference                                                   1.00   Reference      
  Male                         557                        1.00                                           0.82, 1.22                                        .992      0.91   0.75, 1.11    .3667
  Age, years                                                                                                                                                                              
  45--64                       101                        1.00                                           Reference                                                   1.00   Reference      
  65--74                       283                        5.90                                           4.70, 7.41                                        \<.0001   4.80   3.79, 6.09    \<.0001
  ≥75                          298                        11.04                                          8.81, 13.83                                       \<.0001   8.00   6.23, 10.28   \<.0001
  Socioeconomic status                                                                                                                                                                    
  \<20,000                     523                        1.00                                           Reference                                                   1.00   Reference      
  20,000--39,999               143                        0.53                                           0.44, 0.63                                        \<.0001   0.78   0.64, 0.94    .0089
  ≥40,000                      16                         0.13                                           0.08, 0.22                                        \<.0001   0.41   0.24, 0.68    .0006
  Urbanization                                                                                                                                                                            
  Level 1                      198                        1.00                                           Reference                                                                         
  Level 2                      194                        0.91                                           0.75, 1.11                                        0.3558                          
  Level 3                      94                         0.87                                           0.68, 1.11                                        0.27                            
  Level 4                      196                        1.07                                           0.88,1.31                                         0.4785                          
  Comorbidities (Yes vs. No)                                                                                                                                                              
  Hypertension                 393                        2.37                                           2.04, 2.76                                        \<.0001   1.27   1.05, 1.53    .0139
  Diabetes                     114                        1.62                                           1.32, 1.98                                        \<.0001   1.18   0.94, 1.48    .1605
  Coronary artery disease      226                        1.90                                           1.62, 2.23                                        \<.0001   0.81   0.67, 0.98    .0292
  Head injury                  23                         2.18                                           1.44, 3.30                                        .0002     2.17   1.42, 3.30    .0003
  Depression                   7                          1.14                                           0.54, 2.41                                        .7264                           
  Stroke                       122                        2.81                                           2.31, 3.42                                        \<.0001   1.25   1.01, 1.56    .041
  COPD                         250                        2.55                                           2.18, 2.98                                        \<.0001   1.23   0.87, 1.75    .247
  Chronic kidney disease       65                         1.83                                           1.42, 2.36                                        \<.0001   1.15   0.88, 1.51    .3019
  Congestive heart failure     28                         1.90                                           1.30, 2.77                                        .0009     0.75   0.50, 1.11    .1522
  Hyperlipidemia               118                        1.44                                           1.18, 1.76                                        .0004     1.19   0.95, 1.49    .1279
  Obesity                      0                                                                                                                                                           
  Smoking                      287                        2.23                                           1.91, 2.60                                        \<.0001   1.11   0.79, 1.56    .5559
  Alcoholism‐related disease   0                                                                                                                                                           
  Charlson Comorbidity Index                                                                                                                                                              
  0                            129                        1.00                                           Reference                                                   1.00   Reference      
  1                            105                        1.41                                           1.09, 1.83                                        .0088     1.08   0.83, 1.41    .5757
  ≥2                           448                        2.18                                           1.79, 2.65                                        \<.0001   0.98   0.76, 1.25    .8462

Abbreviation: COPD, chronic obstructive pulmonary disease.

Crude HR represented relative hazard ratio.

Adjusted hazard ratio: Multivariate Cox regression model adjusted for age, gender, and significant variables in crude Cox regression model.
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###### 

Incidence and Cox proportional hazard regression with hazard ratios and 95% confidence intervals of dementia associated with and without hernia by gender, age group, and comorbidities

  Variable               Hernia   Compared to Control                                                                                                
  ---------------------- -------- --------------------- ------- ----- -------- ------- ------------------------------------------------------------- -------------------------------------------------------------
  Total                  310      43,095                7.19    372   42,164   8.82    1.23 (1.06, 1.43)[\*\*](#brb31434-note-0012){ref-type="fn"}   1.24 (1.07, 1.45)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Gender                                                                                                                                             
  Female                 57       7,913                 7.20    68    7,652    8.89    1.24 (0.87, 1.76)                                             1.27 (0.89, 1.80)
  Male                   253      35,182                7.19    304   34,512   8.81    1.23 (1.04, 1.45)[\*](#brb31434-note-0011){ref-type="fn"}     1.24 (1.05, 1.47)[\*](#brb31434-note-0011){ref-type="fn"}
  Age group, year                                                                                                                                    
  45--64                 47       24,552                1.91    54    24,230   2.23    1.16 (0.79, 1.72)                                             1.15 (0.78, 1.70)
  65--74                 128      11,815                10.83   155   11,388   13.61   1.27 (1.00, 1.60)[\*](#brb31434-note-0011){ref-type="fn"}     1.26 (1.00, 1.59)
  ≥75                    135      6,728                 20.06   163   6,545    24.9    1.24 (0.99, 1.56)                                             1.24 (0.98, 1.56)
  Socioeconomic status                                                                                                                               
  \<20,000               236      24,744                9.54    287   23,920   12.00   1.26 (1.06, 1.49)[\*\*](#brb31434-note-0012){ref-type="fn"}   1.28 (1.07, 1.52)[\*\*](#brb31434-note-0012){ref-type="fn"}
  20,000--39,999         69       12,705                5.43    74    12,696   5.83    1.07 (0.77, 1.49)                                             1.03 (0.74, 1.43)
  ≥40,000                5        5,647                 0.89    11    5,548    1.98    2.25 (0.78, 6.49)                                             2.48 (0.85, 7.22)
  Urbanization                                                                                                                                       
  Level 1                84       12,237                6.86    114   11,908   9.57    1.40 (1.05, 1.85)[\*](#brb31434-note-0011){ref-type="fn"}     1.45 (1.09, 1.93)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Level 2                88       13,111                6.71    106   12,775   8.30    1.24 (0.93, 1.64)                                             1.26 (0.95, 1.68)
  Level 3                43       6,595                 6.52    51    6,513    7.83    1.20 (0.80, 1.80)                                             1.24 (0.82, 1.86)
  Level 4                95       11,152                8.52    101   10,969   9.21    1.08 (0.82, 1.43)                                             1.07 (0.81, 1.42)
  Comorbidities                                                                                                                                      
  Hypertension                                                                                                                                       
  No                     129      27,128                4.76    160   26,690   5.99    1.26 (1.00, 1.59)[\*](#brb31434-note-0011){ref-type="fn"}     1.25 (0.99, 1.57)
  Yes                    181      15,967                11.34   212   15,473   13.7    1.21 (0.99, 1.47)                                             1.24 (1.02, 1.51)[\*](#brb31434-note-0011){ref-type="fn"}
  Diabetes                                                                                                                                           
  No                     261      38,295                6.82    307   37,436   8.20    1.20 (1.02, 1.42)[\*](#brb31434-note-0011){ref-type="fn"}     1.22 (1.03, 1.44)[\*](#brb31434-note-0011){ref-type="fn"}
  Yes                    49       4,801                 10.21   65    4,728    13.75   1.34 (0.93, 1.94)                                             1.37 (0.94, 1.99)
  CAD                                                                                                                                                
  No                     201      34,099                5.89    255   33,431   7.63    1.3 (1.08, 1.56)[\*\*](#brb31434-note-0012){ref-type="fn"}    1.30 (1.08, 1.56)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    109      8,996                 12.12   117   8,733    13.40   1.11 (0.85, 1.44)                                             1.13 (0.87, 1.46)
  Head injury                                                                                                                                        
  No                     298      42,416                7.03    361   41,476   8.70    1.24 (1.06, 1.45)[\*](#brb31434-note-0011){ref-type="fn"}     1.26 (1.08, 1.47)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    12       679                   17.68   11    688      16.00   0.90 (0.4, 2.05)                                              0.81 (0.34, 1.95)
  Depression                                                                                                                                         
  No                     306      42,698                7.17    369   41,772   8.83    1.23 (1.06, 1.44)[\*\*](#brb31434-note-0012){ref-type="fn"}   1.25 (1.08, 1.46)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    4        397                   10.07   3     392      7.66    0.78 (0.17, 3.49)                                             0.29 (0.04, 2.35)
  Stroke                                                                                                                                             
  No                     253      39,962                6.33    307   39,058   7.86    1.24 (1.05, 1.47)[\*](#brb31434-note-0011){ref-type="fn"}     1.26 (1.06, 1.48)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    57       3,133                 18.19   65    3,106    20.93   1.15 (0.80, 1.63)                                             1.14 (0.80, 1.63)
  COPD                                                                                                                                               
  No                     192      34,910                5.50    240   34,317   6.99    1.27 (1.05, 1.54)[\*](#brb31434-note-0011){ref-type="fn"}     1.28 (1.06, 1.55)[\*](#brb31434-note-0011){ref-type="fn"}
  Yes                    118      8,185                 14.42   132   7,847    16.82   1.17 (0.91, 1.50)                                             1.18 (0.92, 1.52)
  CKD                                                                                                                                                
  No                     281      40,707                6.90    336   39,818   8.44    1.22 (1.04, 1.43)[\*](#brb31434-note-0011){ref-type="fn"}     1.24 (1.06, 1.45)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    29       2,388                 12.14   36    2,346    15.34   1.26 (0.77, 2.05)                                             1.28 (0.78, 2.08)
  CHF                                                                                                                                                
  No                     302      42,083                7.18    352   41,270   8.53    1.19 (1.02, 1.39)[\*](#brb31434-note-0011){ref-type="fn"}     1.20 (1.03, 1.40)[\*](#brb31434-note-0011){ref-type="fn"}
  Yes                    8        1,012                 7.90    20    894      22.36   2.79 (1.23, 6.35)[\*](#brb31434-note-0011){ref-type="fn"}     2.97 (1.29, 6.83)[\*](#brb31434-note-0011){ref-type="fn"}
  Hyperlipidemia                                                                                                                                     
  No                     251      37,482                6.7     313   36,615   8.55    1.28 (1.08, 1.51)[\*\*](#brb31434-note-0012){ref-type="fn"}   1.29 (1.10, 1.53)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    59       5,614                 10.51   59    5,549    10.63   1.01 (0.70, 1.45)                                             1.05 (0.73, 1.50)
  Obesity                                                                                                                                            
  No                     310      43,080                7.20    372   42,148   8.83    1.23 (1.06, 1.43)[\*\*](#brb31434-note-0012){ref-type="fn"}   1.24 (1.07, 1.45)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    0                                                                                                                            
  Smoking                                                                                                                                            
  No                     175      32,265                5.42    220   31,737   6.93    1.28 (1.05, 1.56)[\*](#brb31434-note-0011){ref-type="fn"}     1.29 (1.05, 1.57)[\*](#brb31434-note-0011){ref-type="fn"}
  Yes                    135      10,830                12.47   152   10,427   14.58   1.17 (0.93, 1.48)                                             1.20 (0.95, 1.51)
  ARD                                                                                                                                                
  No                     310      42,941                7.22    372   42,022   8.85    1.23 (1.06, 1.43)[\*\*](#brb31434-note-0012){ref-type="fn"}   1.24 (1.07, 1.45)[\*\*](#brb31434-note-0012){ref-type="fn"}
  Yes                    0                                                                                                                            
  CCI                                                                                                                                                
  0                      54       13,271                4.07    75    13,121   5.72    1.40 (0.99, 1.99)                                             1.36 (0.96, 1.93)
  1                      48       7,804                 6.15    57    7,624    7.48    1.23 (0.83, 1.80)                                             1.26 (0.86, 1.86)
  ≥2                     208      22,020                9.45    240   21,419   11.20   1.19 (0.99, 1.43)                                             1.20 (1,0.00 1.45)

Abbreviations: ARD, alcoholism‐related disease; CAD, coronary artery disease; CCI, Charlson Comorbidity Index; CHF, congestive heart failure; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IR, incidence rates, per 1,000 person‐years; PY, person‐years.

Adjusted hazard ratio: mutually adjusted for gender, age, and baseline comorbidities in Cox proportional hazard regression.

*p*‐Value \< .05.

*p*‐Value \< .01.

John Wiley & Sons, Ltd

![Kaplan--Meier model‐estimated cumulative incidence of dementia in hernia and nonhernia groups in the follow‐up years](BRB3-9-e01434-g002){#brb31434-fig-0002}

4. DISCUSSION {#brb31434-sec-0012}
=============

With a rapid increase in the aging populations worldwide, dementia has become a growing public health problem for which early detection may offer a therapeutic window. Identification of etiological factors for dementia with timely implementation of active interventions targeting the modifiable factors in high‐risk populations may postpone or even prevent clinical onset of the disorder. To date, no published clinical evidence has previously demonstrated a correlation between hernia and dementia. Our study identified hernia as an independent variable associated with a 1.24‐fold increase in risk for dementia development (*p* = .0047), even after adjustment for sex, age, socioeconomic status, urbanization, and medical comorbidities. Furthermore, advanced age, hypertension, head injury, and stroke were shown to be significant risk factors for dementia, while a high socioeconomic status and history of coronary artery disease appeared to be protective against development of the disorder in our cohort study. Although the finding of current study (i.e., 1.24‐fold increase in risk for dementia) may not allow clinicians to select subjects for dementia screening programs, our results highlighted a possible link between hernia and the development of dementia.

In our patients without hernia, the incidence of dementia was 7.19 cases per 1,000 person‐years, which is comparable with that in a previous study (i.e., 9.87 cases per 1,000 person‐years; Chan et al., [2013](#brb31434-bib-0008){ref-type="ref"}). The age‐adjusted prevalence of all‐cause dementia has been reported to be 8.04% in Taiwan (Sun et al., [2014](#brb31434-bib-0034){ref-type="ref"}). It was estimated that the dementia‐stricken population was up to 36.5 million worldwide in 2010, with 7.7 million new cases being diagnosed each year (i.e., a new case every 4 s; Sosa‐Ortiz, Acosta‐Castillo, & Prince, [2012](#brb31434-bib-0033){ref-type="ref"}). In the United States, official death records in 2013 showed 84,767 deaths from AD, making it the sixth leading killer and the fifth leading cause of death among the elderly (i.e., ≥ 65 years; Alzheimer\'s Association, [2016](#brb31434-bib-0001){ref-type="ref"}). Productivity equivalent to more than \$221 billion was wasted in 2015 alone as over 15 million family members as well as other unpaid caregivers devoted themselves to the care of American populations afflicted with Alzheimer and other dementias (Alzheimer\'s Association, [2016](#brb31434-bib-0001){ref-type="ref"}).

Despite current advances in the diagnosis of mental diseases, diagnosis of dementia remains challenging to physicians in primary care and is prone to be delayed or missed (Boustani et al., [2005](#brb31434-bib-0006){ref-type="ref"}). There is no previous study reporting the possible relationship between hernia and dementia. Taking into account the action of MMP, which is a possible link between the two clinical entities, the present study attempted to identify their possible association. The results showed a 1.24‐fold increase in risk for subsequent development of dementia in patients with hernias compared to those without. These findings carried several striking clinical implications. First, in view of the potential risk for subsequent dementia, potential screening strategies may be implemented for early detection of the disease for high‐risk patients (e.g., advanced age) with co‐existing hernia. Second, patients with hypertension, head injury, or stroke may also be chosen for dementia screening programs. Consistent with the findings of the present study, satisfactory cardiovascular risk factor control has been reported to delay or even prevent the development of dementia (Patterson et al., [2008](#brb31434-bib-0025){ref-type="ref"}). Third, MMP may be a potential target in the treatment of dementia, although the clinical significance remains to be elucidated.

Multivariate analysis showed that patients with advanced age (≥65 years), low socioeconomic status, hypertension, head injury, and stroke exhibited significantly higher risks of developing dementia, after adjusting for covariates. The findings support those from previous studies identifying these comorbidities as potential risk factors for dementia (Goldbourt, Schnaider‐Beeri, & Davidson, [2007](#brb31434-bib-0012){ref-type="ref"}; Jorm & Jolley, [1998](#brb31434-bib-0014){ref-type="ref"}; Kohler et al., [2015](#brb31434-bib-0017){ref-type="ref"}; Poblador‐Plou et al., [2014](#brb31434-bib-0026){ref-type="ref"}; Qiu et al., [2010](#brb31434-bib-0028){ref-type="ref"}; Sahathevan et al., [2012](#brb31434-bib-0032){ref-type="ref"}). However, the finding of coronary artery disease being protective against the development of dementia in the current study remains poorly explained. In addition, there was no significant gender difference in dementiariskin the present cohort (Table [2](#brb31434-tbl-0002){ref-type="table"}). While the finding was in concert with that of some previous studies (Jorm & Jolley, [1998](#brb31434-bib-0014){ref-type="ref"}; Yang et al., [2016](#brb31434-bib-0037){ref-type="ref"}), it was different from that of other studies reporting a higher risk of Alzheimer disease or dementia in women than in men (Gao, Hendrie, Hall, & Hui, [1998](#brb31434-bib-0011){ref-type="ref"}; Sun et al., [2014](#brb31434-bib-0034){ref-type="ref"}).

Hernia formation and recurrence are often linked to distorted collagen metabolism caused by MMPs in fascia transversalis (Antoniou et al., [2011](#brb31434-bib-0002){ref-type="ref"}, [2009](#brb31434-bib-0003){ref-type="ref"}; Franz, [2008](#brb31434-bib-0010){ref-type="ref"}; Henriksen et al., [2011](#brb31434-bib-0013){ref-type="ref"}). In the brain, MMPs play multiple roles ranging from synaptic plasticity, brain development, maintaining normal physiological functions, and recovery after injury (Kim & Joh, [2012](#brb31434-bib-0016){ref-type="ref"}; Mroczko et al., [2013](#brb31434-bib-0024){ref-type="ref"}; Rempe et al., [2016](#brb31434-bib-0029){ref-type="ref"}; Rosenberg, [2009](#brb31434-bib-0030){ref-type="ref"}; Weekman & Wilcock, [2016](#brb31434-bib-0035){ref-type="ref"}). On the other hand, accumulating evidence suggests that MMPs may play a pivotal role in the pathogenesis of several neurodegenerative disorders including multiple sclerosis, AD, Parkinson\'s disease, malignant glioma, neuroinflammation, and ischemia (Kim & Joh, [2012](#brb31434-bib-0016){ref-type="ref"}; Mroczko et al., [2013](#brb31434-bib-0024){ref-type="ref"}; Rempe et al., [2016](#brb31434-bib-0029){ref-type="ref"}; Rosenberg, [2009](#brb31434-bib-0030){ref-type="ref"}; Weekman & Wilcock, [2016](#brb31434-bib-0035){ref-type="ref"}). Although the mechanism remains unclear, dysregulation of MMPs may be an important factor linking hernia and dementia.

The major strength of the current investigation was the utilization of a nationwide population‐based database as well as the longitudinal, observational design together with a lengthy follow‐up. For the purpose of the present study, all insurance claims were examined and coded by trained medical reimbursement staff as well as peer‐reviewed in accordance with the standard criteria for diagnoses. Because incorrect diagnoses or erroneous coding would result in heavy penalties for physicians, the diagnoses and coding used in this study should be highly reliable. In addition, selection biases were minimized because NHIRD are highly representative of the health information of Taiwan\'s general population. Risks had been well adjusted in the present study. Besides, statistical power was reinforced by the large sample size to consolidate the results. Furthermore, the longitudinal design allowed elucidation of the temporal association between dementia and hernia, which could help establish a potential positive correlation.

On the other hand, subgroup analysis was not performed on different types of abdominal hernias because inguinal hernia is known to constitute the large majority of cases. Although MMPs may have a role to play in the recurrence of inguinal hernia, (Antoniou et al., [2011](#brb31434-bib-0002){ref-type="ref"}, [2009](#brb31434-bib-0003){ref-type="ref"}) we did not analyze the association between dementia and inguinal hernia recurrence because several modifiable and nonmodifiable contributors to hernia recurrence including perioperative (e.g., the surgeon---learning curve and caseload), patient (age, body mass index), and hernia (e.g., direct inguinal hernias vs. indirect inguinal hernias) factors have been reported (Ashrafi, Siddaiah‐Subramanya, Memon, & Memon, [2019](#brb31434-bib-0004){ref-type="ref"}). Besides, taking into account the limited sample size of our study, an estimated rate of 13% for surgical repair of recurrent inguinal hernias among all inguinal hernia operations (Ashrafi et al., [2019](#brb31434-bib-0004){ref-type="ref"}) would further diminish the study population and blemish the accuracy of risk assessment. Additionally, despite being a common clinical observation, the association between increase in abdominal pressure (e.g., chronic cough and constipation) and the development of hernias remains controversial (Ruhl, [2007](#brb31434-bib-0031){ref-type="ref"}). Although previous studies reported the presence of obstipation (Liem, van der Graaf, Zwart, Geurts, & van Vroonhoven, [1997](#brb31434-bib-0019){ref-type="ref"}) or chronic cough (Ruhl, [2007](#brb31434-bib-0031){ref-type="ref"}) may increase the risk of inguinal hernia in female patients, this association was not found in their male counterparts in a large‐scale study (Ruhl, [2007](#brb31434-bib-0031){ref-type="ref"}). Also, taking into consideration possible bias arising from listing the diagnoses of "chronic cough" and "chronic constipation" as independent variables for analysis because of the lack of clear definitions, these conditions were not included for further evaluation.

Caution should be taken in the interpretation of our results due to several limitations in the current study. First, our study has the inherent limitations pertaining to the use of a retrospective database (e.g., selection bias and misclassification bias). Second, as the symptom of dementia may be unrecognized and the demented patients may not seek active medical care, some cases with dementia may be missed. However, it could be assumed that the probability of missing the diagnosis was the same for both groups in our study because of the large sample size. Third, even though socioeconomic factors and urbanization level of the enrollees have been considered in this study, levels of education (Karp et al., [2004](#brb31434-bib-0015){ref-type="ref"}; Sun et al., [2014](#brb31434-bib-0034){ref-type="ref"}) and social disengagement (Bassuk, Glass, & Berkman, [1999](#brb31434-bib-0005){ref-type="ref"}), which are known confounders for dementia, were not available in the NHIRD. In addition, previous occupation, physical activity, family history of hernia, and mobility are also potential confounders for hernia. Matching for these confounders would have improved the validity of our results. Fourth, information on laboratory studies, imaging findings, or symptom severity of dementia, which were inherent limitations of the insurance claims data, was unavailable for further analysis. Fifth, matching comorbidities for subject selection also meant reduction of sample size and increased risk for bias. Additionally, the incidence of dementia may vary in HIV‐infected patients depending on whether antiretroviral therapy is used (Larussa et al., [2006](#brb31434-bib-0018){ref-type="ref"}). To avoid biasing our results, HIV‐infected patients were excluded.

In conclusion, the results of the current nationwide, population‐based longitudinal study provided evidence in support of a temporal association between abdominal wall hernia and the risk of dementia irrespective of the subjects\' age, sex, socioeconomic factors, urbanization, and comorbidities. Advanced age (i.e., ≥65 years), low socioeconomic status (\<20,000), hypertension, head injury, and stroke showed significant associations with dementia. Despite these findings, the results of our study should be validated in further prospective studies with larger samples.
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